FDAsafety guidance77% confidence
Ongoing | Cancer Accelerated Approvals
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Sciegen Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Supporting Context
- Therapeutic area
- Pain Management · NSAID
- Sub-indication
- Pain
Related signal: FDA Grants Approval for Naproxen Sodium ANDA212199 by Sciegen Pharmaceuticals